Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.
Martin P, Dirks B, Gertsik L, Walling D, Stevenson A, Corcoran M, Raychaudhuri A, Ermer J. Martin P, et al. Among authors: gertsik l. J Clin Psychopharmacol. 2014 Dec;34(6):682-9. doi: 10.1097/JCP.0000000000000205. J Clin Psychopharmacol. 2014. PMID: 25310201 Clinical Trial.
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.
Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. Fava M, et al. Among authors: gertsik lg. Mol Psychiatry. 2016 Oct;21(10):1372-80. doi: 10.1038/mp.2015.178. Epub 2015 Dec 8. Mol Psychiatry. 2016. PMID: 26643541 Free PMC article. Clinical Trial.
A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events.
Goldsmith P, Affinito J, McCue M, Tsai M, Roepcke S, Xie J, Gertsik L, Macek TA. Goldsmith P, et al. Among authors: gertsik l. Drugs R D. 2017 Dec;17(4):631-643. doi: 10.1007/s40268-017-0214-8. Drugs R D. 2017. PMID: 29103081 Free PMC article. Clinical Trial.
Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial.
Nations KR, Dogterom P, Bursi R, Schipper J, Greenwald S, Zraket D, Gertsik L, Johnstone J, Lee A, Pande Y, Ruigt G, Ereshefsky L. Nations KR, et al. Among authors: gertsik l. J Psychopharmacol. 2012 Dec;26(12):1525-39. doi: 10.1177/0269881112458728. Epub 2012 Sep 6. J Psychopharmacol. 2012. PMID: 22954616 Clinical Trial.
Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia.
Desai A, Benner L, Wu R, Gertsik L, Maruff P, Light GA, Uz T, Marek GJ, Zhu T. Desai A, et al. Among authors: gertsik l. Neuropsychopharmacology. 2021 May;46(6):1145-1151. doi: 10.1038/s41386-020-00908-0. Epub 2020 Nov 17. Neuropsychopharmacology. 2021. PMID: 33203954 Free PMC article. Clinical Trial.
23 results